Abbott, Alere Settle Watchdogs' Issues With $5.3B Deal

Law360, New York (September 28, 2017, 8:11 PM EDT) -- U.S. and Canadian antitrust regulators revealed Thursday that pharmaceutical giant Abbott Laboratories and diagnostic service provider Alere Inc. have settled the agencies' concerns over Abbott's $5.3 billion bid for Alere.

Under the deals with the Federal Trade Commission and the Canada's Competition Bureau, Massachusetts-based Alere has agreed to sell off its Epoc blood gas testing system and Ottawa facilities to Siemens AG and Alere's Triage cardiac marker testing system and a San Diego facility to Quidel Corp.

Illinois-based Abbott unveiled its $5.8 billion bid for Alere in February 2016 in an effort to bolster Abbott's point-of-care and diagnostic offerings. A month...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!